CLEO Receives First Batch of Commercial Test Kits
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the receipt of its first batch of commercially manufactured test kits for ovarian cancer diagnostics, marking a significant milestone in its regulatory program. The company will commence its Analytical Validation program to evaluate the performance of its eight-biomarker assay using these test kits. The CEO emphasized the importance of this milestone in progressing towards clinical results and eventual commercialization of the test.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- Change of Director's Interest Notice x 4
- Cleansing Notice
- Application for quotation of securities - COV
- Notification of cessation of securities - COV
- Change in Director's Interest Notice
Later from CLEO Diagnostics
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- Notice Required Under ASX Listing Rule 3.13.1
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders
- CLEO Commences Ovarian Cancer Screening Test Development
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics